Category Archives: Psoriasis

Psoriasis Drug Market Growth Opportunities and Forecast to 2026:

The Global Psoriasis Drug Market industry research report begins with an elementary prologue to Psoriasis Drug showcases alongside product definition, product scope, market overview, product characterization, and specification. The global Psoriasis Drug Market was valued at a billion USD in 2018 and is expected to reach a billion USD by 2026 with an anticipated CAGR of during the forecast period, 20192026. The information mentioned in the Global Psoriasis Drug Market research report presents an overview of the latest trends observed in the global market. Besides, this intelligence study focuses on the latest events such as the technological developments and the product launches and their consequences on the Global Psoriasis Drug Market. Furthermore, the research report presents the potential industry supply, market demand, market value, market competition, key market players and the industry estimate from 2019-2026.

Grab a Free Sample PDF copy of the Psoriasis Drug Market Report 2019 @ https://straitsresearch.com/report/Psoriasis Drug-Market/request-sample

The Major Players Covered in this Report: Amgen Inc., Celgene Corporation, AbbVie Inc., Johnson & Johnson, Novartis, Eli Lilly, AstraZeneca, and Pfizer are some of the key market players.

These players are focusing on expanding their business in developing countries or emerging markets, like India, China, and South Korea, through coalitions and acquisitions for the development of novel products. The development of biosimilars is more commonly adopted By these companies. & More.

A comprehensive analysis of contemporary trends, demand spectrum, growth rate, and key region-wise Psoriasis Drug market exploration has also been embodied in this report. There are speculations about Global Psoriasis Drug Market to strongly dominate the global economy with a substantial growth rate in the coming years. Promptly developing industry infrastructure, increased product commercialization, and drifting demands of the Psoriasis Drug are strengthening Psoriasis Drug industrys footholds to become more influential and significantly contribute in international revenue generation.

The report is a valued asset for the active players, new participants, and future investors, and provides a comprehensive assessment across regions such as:

Growing Domestic Demand and Expanding Pharmaceutical Sector to Drive the Demand for Psoriasis Drug in the APAC RegionAsia-Pacific region is anticipated to hold the largest market share in the global Psoriasis Drug market during the forecast period 2017-2026. The growth in this region can be attributed to the presence of emerging economies like India, China, Japan, Vietnam, and Indonesia, which account for the largest share in this region. India is one of the largest producers of Psoriasis Drug and a major exporter of the product to various countries across the globe. India accounts for around 80% of the worlds exports of Psoriasis Drug. The favorable climatic conditions and growth of agricultural inputs and allied services like cold storage and warehousing in India are prompting higher production.

COVID-19 Impact Analysis: The COVID-19 pandemic had a significant impact on the on trade segment and Industry. Manufacturers are comprehending strategies to revive from the current situation by means of reshaping their sales channels as well as product innovation. The duration of the virus outbreak remains a key factor in assessing the overall impact of the pandemic. However, the global Railway Suspension System industry is expected to stabilize after 2019. The liquor industry was not impacted severely due to the pandemic.

Full Report Link @ https://straitsresearch.com/report/Psoriasis Drug-market

2 Research Methodology2.1 Primary Research2.2 Research Methodology2.3 Assumptions & Exclusions2.4 Secondary Data Sources

3 Executive Summary4 Market Overview4.1 Report Segmentation & Scope4.2 Value Chain Analysis: AR and VR Headset Market4.2.1 Vendor Matrix4.3 Key Market Trends4.3.1 Drivers4.3.2 Restraints4.3.3 Opportunities4.4 Porters Five Forces Analysis4.4.1 Bargaining Power of Suppliers4.4.2 Bargaining Power of Buyers4.4.3 Threat of Substitution4.4.4 Threat of New Entrants4.4.5 Competitive Rivalry4.5 Environment & Regulatory Landscape4.6 Forecast Factors & Relevance of Impact4.7 Macro-Economic & Geopolitical Scenario4.8 Parent Market Overview4.9 Technology Landscape4.10 Market Share Analysis4.11 Potential Venture Analysis4.12 Regional Price Trends4.13 Raw Material Trends4.14 Covid-19 Impact Analysis4.14.1 Pre Covid-19 Market Scenario Analysis4.14.2 Post Covid-19 Market Scenario Analysis4.14.3 Measures Taken by Top Players4.14.4 Quarterly Market Revenue and Growth Forecast till 20194.15 Cost Structure Analysis4.15.1 Labor Cost4.15.2 Consumables4.15.3 Maintenance Cost

5 Type Overview5.1 Introduction5.1.1 Market Size & Forecast (Value & Volume)5.2 AR Headset5.2.1 Market Size & Forecast (Value & Volume)5.3 VR Headset5.3.1 Market Size & Forecast (Value & Volume)5.4 AR/VR Headset5.4.1 Market Size & Forecast (Value & Volume)

6 Product Type Overview6.1 Introduction6.1.1 Market Size & Forecast (Value & Volume)6.2 Standalone6.2.1 Market Size & Forecast (Value & Volume)6.3 Tethered6.3.1 Market Size & Forecast (Value & Volume)6.4 Screenless Viewer6.4.1 Market Size & Forecast (Value & Volume)Continue..

StraitsResearch:(straitsresearch.com) is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

Read the original post:
Trend Expected to Guide Psoriasis Drug Market from 2019-2026: Growth Analysis by Manufacturers, Regions, Type and Application. KSU | The Sentinel...

Psoriasis Marketresearch report is the new statistical data source added byOneup Business Insights.

In 2019, the global Psoriasis Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

The current environment of the ever-evolving business sector, as well as the existing and prospective implications of COVID-19 on the market, are examined in this research. Each business covered in the research report is examined in terms of product and application portfolios, market share, growth potential, future plans, and development activities such as mergers and acquisitions, product introduction, and so on.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @

https://www.oneupbusinessinsights.com/request_sample.php?tname=14579

Top key players @ Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services, LLC), Novartis AG, and Amgen Inc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key market trends impacting the growth of the Global Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

More Information:

https://www.oneupbusinessinsights.com/enquiry_before_buying.php?tname=14579

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.oneupbusinessinsights.com/askfor_discount.php?tname=14579

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Oneup Business Insights is an obligated organization and a global groundbreaker in research, analytics and advisory. We create advance informative reports that will assist you to transform your business, amend your approach and take decisions valiantly.

Oneup Business Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SMEs, start-ups, financial technology start-ups, and venture capitalists.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Oneup Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Vick Batho

(Assistant Manager Business Development)

US: +1 315 675 7779

3811 Ditmars Blvd, Astoria, NY-1115

sales@oneupbusinessinsights.com

http://oneupbusinessinsights.com/

Continue reading here:
Psoriasis Market 2021-Competitive Insights: Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services, LLC), Novartis AG The...

New research shows that switching from a Western diet to a balanced diet could help you reduce skin and joint inflammation. The study led by UC Davis Health researchers states that the reduction may be due to a better-balanced gut microbial culture.

Published in the Journal of Investigative Dermatology, the study suggests that cutting out sugar and fat and consuming a more balanced diet can help you restore gut health, which can suppress skin inflammation that may otherwise contribute to inflammatory skin diseases such as psoriasis.

Psoriasis is a chronic skin condition linked to the bodys immune system. Healthy skin cells are attacked mistakenly by immune cells, which cause skin inflammation and the formation of scales and itchy red patches.

Approximately 30% of patients with psoriasis also have psoriatic arthritis, which causes morning stiffness and fatigue, pain in joints, swollen fingers and toes, and changes to nails.

Previous studies have shown how diet can influence psoriasis through microbial balance in the intestines and skin inflammation. Consuming a traditional Western diet can cause a rapid change to the guts microbial community and its functions. This disruption, called dysbiosis, can contribute to gut inflammation.

For the new study, researchers wanted to test whether intestinal dysbiosis affects skin and joint inflammation. A mouse model was used to study the effects of diet on psoriasis and psoriatic arthritis. The mice were injected with Interleukin-23 (IL-23) minicircle DNA to induce a response mimicking psoriasis-like skin and joint diseases.

IL-23 is a protein created by the immune cells responsible for many inflammatory autoimmune reactions. This includes psoriasis and inflammatory bowel disease (IBD).

Researchers found that a short-term Western diet appears sufficient to cause microbial imbalance and to enhance susceptibility to IL-23 proteins that can lead to skin inflammation.

There is a clear link between skin inflammation and changes in the gut microbiome due to food intake, said Sam T. Hwang, study author. The bacterial balance in the gut disrupted shortly after starting a Western diet, and worsened psoriatic skin and joint inflammation.

The study went on to show that eating a diet high in sugar and fat is a major contributor to skin and joint inflammation. However, it can be changed by switching to a more balanced diet. The improvement in skin inflammation seen in mice taken off the Western diet indicated a short-term impact of the Western diet on skin inflammation.

Researchers concluded the study by suggesting that changes in diet could partially reverse the proinflammatory effects and alteration of gut microbiota caused by the Western diet.

Go here to read the rest:
Study States That Diet Rich in Sugar and Fat Contributes to Skin & Joint Inflammation - Bel Marra Health

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the University of Barcelona, led by lead investigator Dr. Luis F Santamaria-Bab, Ph.D. to investigate the modulatory effect of targeted therapies in models of inflammatory skin disease. The research study will use DermTechs Smart StickerTM-enabled platform to interrogate inflammatory pathways underlying the pathogenesis of atopic dermatitis (AD) and psoriasis. In vitro models of AD and psoriasis will also be used to evaluate the modulatory effect of targeted therapies on these inflammatory pathways. The research collaboration highlights DermTechs commitment to using precision genomics and personalized dermatology approaches to improve the identification of effective therapies and better understanding of dermatological diseases.

AD is a chronic inflammatory skin disease characterized by intense itching that affects approximately 15-20% of children and up to 10% of adults in the US and Europe. Psoriasis is an autoimmune skin disease characterized by red, scaly skin lesions formed by the hyperproliferation of epidermal keratinocytes, and it affects approximately 3% of the adult population in the US and Europe. Both AD and psoriasis have significant negative social and economic impacts on patients and their families. The increasing number of therapies for AD and psoriasis in clinical development add to a growing armamentarium for physicians and support the need for more personalized approaches to patient care.

We are very delighted to collaborate in precision dermatology with DermTech, said Dr. Luis F. Santamaria-Bab, Ph.D., Professor of Immunology and head of Translational Immunology Group at the University of Barcelona at the Parc Cientfic de Barcelona.

Through precision genomics, it is now possible to identify complex genetic and immunological factors that play a role in the pathogenesis of inflammatory skin diseases such AD and psoriasis, said Michael Howell, Ph.D., DermTechs chief scientific officer. We believe that this collaboration will increase our understanding of how these targeted therapies work in some patients and provide insight on personalized approaches to treatment for AD and psoriasis.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTechs mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTechs investor relations site at: http://www.dermtech.com.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as expect, estimate, project, budget, forecast, anticipate, intend, plan, may, will, could, should, believes, predicts, potential, continue, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, costeffectiveness, commercialization and adoption of DermTechs products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTechs ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTechs tests; (4) the reimbursement of DermTechs tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTechs products; (6) DermTechs ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTechs products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the Risk Factors section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the SEC), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Read the original:
DermTech to Partner with University of Barcelona for Research Study on Atopic Dermatitis and Psoriasis - Business Wire

The skin is the largest organ in the body it protects the body from trauma and serves other functions like regulating body temperature. Psoriasis is an autoimmune condition that impacts the skin, presenting itself as red, scaly patches that affect different body parts.

Psoriasis occurs when the immune system attacks healthy skin tissue, but little is known about why this happens.The condition can affect people of any age, and is considered equally prevalent among men and women.

The World Health Organization categorizes psoriasis as a serious global problem that affects at least 10 million people worldwide. Psoriasis is widely considered to be the most stigmatized of all skin disorders.

Researchers and patients with psoriasis point out that misconceptions about the condition decrease the quality of life for people, and note that more awareness is needed on the subject. This has led to initiatives like the Get Your Skin Out Movement and similar body-positive campaigns to understand how psoriasis affects people.

Psoriasis is a long-term condition that presents itself most commonly as a rash on the skin. The most common areas affected by psoriasis include the scalp, knees, and elbows but other parts of the body such as the ears and neck can also be affected.As an autoimmune skin condition, it is the result of an overactive immune system. It causes the skin cells to multiply up to 10 times faster than normal making the skin build up into bumpy redpatches. For some people, these patches itch, burn, and sting.Inflammation caused by psoriasis is also known to impact other organs and tissues in the body.

The WHO recognizes psoriasis as a condition attached with a lot of stigma, thereby associated with a decreased quality of life. People who suffer from psoriasis are at risk of developing mental illnesses such as depression. There are also a range of other associated illnesses such as Inflammatory Bowel Disease (IBD), cardiovascular disease, diabetes, and others.

While the condition is not contagious, there is currently no permanent cure.

While not much is known about what causes psoriasis, environment and genetics play a role in determining who is more vulnerable. Common risk factors include family history, smoking, and stress the latter two are associated with weakened immune systems, and therefore may make one more susceptible to developing the autoimmune condition.

Psoriasis usually presents itself in early adulthood, but people of all ages, skin colors, and genders can experience it.

Related on The Swaddle:

All You Need To Know About Alopecia

Plaque psoriasis is the most common type of psoriasis. The condition occurs in cycles, or flare-ups, of a rash. The average period between each flareup can be anywhere between one to 12 months. Flare-ups usually come with the following symptoms:

There are, however, other types of psoriasis which affect other parts of the body. They have their own symptoms:

As an autoimmune condition, psoriasis is triggered when the immune system mistakes cells of the body as external harmful agents such as bacteria or viruses, and mounts a response against them. The immune system causes inflammation, which in turn triggers faster cell growth. So while healthy skin cells shed and grow every 28-30 days, people with psoriasis experience skin cell growth every 3-4 days. When the skin grows faster than it is shed, the cells build up to form the red scaly appearance which is visible on the skin surface.

Psoriasis is often triggered by certain immune-related or external factors. Triggering events include infections, injuries, and changing lifestyle habits that may impact the immune system, leading to the onset of symptoms.

External elements include skin or throat infections, cold or dry weather, skin injuries, stress, smoking, high alcohol consumption, and certain medications.

Although there is no permanent cure for psoriasis, treatment options exist to manage symptoms and reduce the risk of other associated diseases. Topical treatments in the form of applying medication on the skin, through ointments and creams, help slow down cell reproduction and inflammation.

Phototherapy is another strategy, in which doctors use artificial Ultraviolet B (UVB) light to slow the growth of skin cells. Other therapies that focus on making diet and lifestyle changes are also a way of treating the condition although their success varies from person to person.

Read the original post:
All You Need To Know About Psoriasis - The Swaddle

(WYTV) Your dentist has no doubt told you to keep your gums healthy. Now were learning the bacteria in your mouth could contribute to a common skin condition psoriasis.

More than 8 million Americans suffer from psoriasis. The cause remains largely a mystery but a key to improving your skin may begin with your mouth.

Doctors at the Ohio State Wexner Medical Center asked patients about their oral hygiene and found a link between poor gum health and more severe psoriasis.

We know that patients who have poor gum health, periodontitis, have a higher prevalence of pathogenic bacteria in the first place, said Dr. Benjamin Kaffenberger, a dermatologist.

Want to deal with your psoriasis? Brush and floss, maintain a healthy weight, avoid alcohol and smoking, and get plenty of fruit in your diet.

Ohio State is collecting data on this, trying to reach psoriasis patients around the country to ask them about their dental health, diets and lifestyles.

Read more from the original source:
Researchers find connection between dental health and psoriasis - WYTV

Corresponding author George Kuo, PhD, of the Linkou Chang Gung Memorial Hospital, in Taiwan, and colleagues, explained that it has previously been shown that patients with psoriasis face a higher risk of HZ infection.

However, the association between HZ risk and different systemic therapies, especially biologic agents, remains controversial, they wrote.

Biologic agents can be highly effective at treating psoriasis, but they also result in suppression of cell-mediated immunity, raising the risk that they increase risk of bacterial and viral infections.

Kuo and colleagues sought to understand the risk on a therapy-by-therapy basis. To do so, they identified 92,374 patients in the Taiwan National Health Insurance Research Database who were newly diagnosed with psoriasis between 2001 and 2013. The investigators tracked these patients for a median of 6.8 years, noting the use of anti-psoriasis therapies and looking for diagnoses of HZ infection.

In all, 4834 patients (5.2%) were diagnosed with HZ. The authors found that older age, female sex, hypertension, dyslipidemia, psoriatic arthritis, and a relatively high Charleston comorbidity index score were all associated with increased risk of HZ infection. Concurrent exposure to steroids and statins was also linked with an increased risk. However, the 3 therapies identified as increasing HZ risk each more than quadrupled the risk of infection: etanercept (HR, 4.78; 95% CI, 1.5115.17); adalimumab (HR, 5.52; 95% CI, 1.7217.71); and methotrexate plus azathioprine (HR, 4.17; 95% CI, 1.789.82).

Kuo and colleagues said this is the first report to link etanercept and adalimumab to HZ infection. In addition to finding that methotrexate plus azathioprine significantly increased the risk, they also found that methotrexate combined with any biologic agent increased risk, though not to a statistically significant level.

Another biologic, ustekinumab (Stelara) was also studied, and none of those patients became infected with HZ. However, Kuo and colleagues said that could be due to the fact that it was not approved in Taiwan until 2011, and therefore there was a limited amount of follow-up time for those patients in the study.

Conversely, 2 psoriasis treatmentsphototherapy and acitretin (Soriatane)were associated with a lower risk of psoriasis. Phototherapy had a HR of 0.76 (95% CI, 0.600.96) and acitretin had a HR of 0.39 (95% CI, 0.240.64). Kuo and colleagues said the lower risk associated with acitretin may be due to the lower level of immunosuppression associated with acitretin monotherapy. In the case of phototherapy, which uses UV light, they suggested that the benefit is linked with the increased level of vitamin D associated with UV exposure. Earlier reporting has suggested that vitamin D therapy can lower the risk of HZ.

The authors noted limitations including the unavailability of several other biologics at the time of the study, and a lack of data related to psoriasis severity, which limited their ability to adjust their findings based on severity or laboratory results. However, they noted that in previous studies, the use of systemic therapies or a psoriatic arthritis diagnosis have been used as proxies for labeling cases moderate to severe, suggesting that the patients in this study could be assumed to be in the same category.

Reference

Ting SW, Ting SY, Lin YS, Lin MS, Kuo G. Risk of herpes zoster in psoriasis patients receiving systemic therapies: a nationwide population-based cohort study. Sci Rep. Published online June 3, 2021. doi:10.1038/s41598-021-91356-3

Follow this link:
Systemic Therapies Linked With Herpes Zoster Risk in Patients With Psoriasis - AJMC.com Managed Markets Network

The research report presents a comprehensive assessment of the Psoriasis Market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. Psoriasis with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. Psoriasis market future, competitive analysis by Psoriasis Market Players, Deployment Models, Opportunities, Future Roadmap, Value Chain, Major Player Profiles.

Psoriasis market report records and concentrates the main rivals likewise furnishes the bits of knowledge with vital industry Analysis of the key elements impacting the market. Psoriasis Market Report contains revenue numbers, product details, and sales of the major firms. Additionally, it provides a breakdown of the revenue for the global Psoriasis market. The report contains basic, secondary and advanced information pertaining to the Psoriasis Market global status and Psoriasis market size, share, growth, trends analysis, segment and forecast.

Global psoriasis market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period.

Get Free PDF Sample Copy of This Report:- https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-psoriasis-market#utm_source=KA

Market Report Scope:

Countries and Geographies: The geographical regions data will help you in targeting all the best-performing regions. The section covers: (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China)

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-psoriasis-market#utm_source=KA

The Objectives of the Psoriasis Market Report:

Psoriasis Market competition by top manufacturers/players, with sales volume, Price (USD/Unit), Revenue (Million USD) and market share for each manufacturer/player; the top players including:

Novartis AG, Pfizer Inc., Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Abbvie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Johnson & Johnson Services, Inc, AstraZeneca and others. .

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart): https://www.databridgemarketresearch.com/toc/?dbmr=global-psoriasis-market#utm_source=KA

Major Points Covered in Psoriasis Market Report:-

Have Any Query? Ask Our Expert at: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-psoriasis-market#utm_source=KA

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

See more here:
Psoriasis Market Analysis, Size, Regional Outlook, Competitive Strategies and Forecasts to 2027 The Manomet Current - The Manomet Current

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Mechelen, Belgium; 22 June 2021, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year.

Dr. Piet Wigerinck joined Galapagos as Senior Vice President Development in 2008 and became Chief Scientific Officer in 2012, overseeing the discovery of novel drug targets through to clinical Proof-of-Concept studies. He led his teams through the very first clinical research done in healthy volunteers at Galapagos and was responsible for the Phase 2 FITZROY and DARWIN programs for filgotinib, which later became Galapagos first commercial product Jyseleca. Under his leadership, Galapagos achieved a significant portfolio of over 100 patent families.

Effective immediately, all early-stage development activities will be added to late-stage clinical development under the responsibility of Chief Medical Officer Dr. Walid Abi-Saab. Piet will remain with the company the coming five months to steer progression of early research while a new leader is sought.

We are grateful to Piet for his strong scientific leadership over the years. Piets vision to identify novel druggable targets has resulted in a large, data-rich pipeline of promising molecules in multiple disease areas which ultimately was partnered with Gilead in a landmark deal. The results with TYK2 inhibitor GLPG3667 and the patient studies with Toledo molecule GLPG3970 expected this summer form part of his considerable legacy, said Onno van de Stolpe, CEO of Galapagos.

Galapagos retains all guidance for full year 2021 newsflow, including the report of topline results this summer from a Phase 1b trial with TYK2 inhibitor GLPG3667 in psoriasis, and three patient studies with lead Toledo candidate SIK2/3 inhibitor GLPG3970 in psoriasis, ulcerative colitis, and rheumatoid arthritis.

About Galapagos

Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at http://www.glpg.com.

This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).

Except for filgotinibs approval for the treatment of rheumatoid arthritis by the European Commission and Japanese Ministry of Health, Labour and Welfare, our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority.

Jyseleca is a trademark of Galapagos NV and Gilead Sciences, Inc. or its related companies.

Contact

Investors:Elizabeth GoodwinVP Investor Relations +1 781 460 1784

Sofie Van GijselSenior Director Investor Relations+32 485 19 14 15ir@glpg.com

Media:Carmen VroonenGlobal Head of Communications & Public Affairs+32 473 824 874

Evelyn FoxDirector Executive Communications+31 6 53 59 19 99communications@glpg.com

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to dier materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent risks associated with clinical trial and product development activities, competitive developments, and regulatory approval requirements, including the risk that data from the ongoing and planned clinical research programs in rheumatoid arthritis, Crohns disease, ulcerative colitis, idiopathic pulmonary fibrosis, osteoarthritis, and other inflammatory indications may not support registration or further development due to safety, efficacy or other reasons, the timing or likelihood of regulatory authorities approval of marketing authorization for filgotinib for RA, UC or any other indication, such regulatory authorities requiring additional studies, changes in our management board and key personnel, our ability to effectively transfer knowledge during this period of transition, the search and recruitment of a suitable successor to lead our research organization, Galapagos strategic R&D ambitions, including progress on our fibrosis portfolio, and potential changes of such ambitions, Galapagos reliance on collaborations with third parties, including the collaboration with Gilead for filgotinib, the uncertainty regarding estimates of the commercial potential of filgotinib, the timing of and the risks related to implementing the amendment of our arrangement with Gilead for the commercialization and development of Jyseleca (filgotinib), the uncertainties relating to the impact of the COVID-19 pandemic and our strategy, business plans and focus, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2020 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on managements current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

Go here to read the rest:
Galapagos announces departure of CSO Piet Wigerinck later this year - StreetInsider.com

Psoriasis scales are a characteristic sign of psoriasis. They typically appear as patches of rough, red skin and silvery-white scales that may itch, cause discomfort, and flake away. There are a few methods people can try to manage their skin and remove psoriasis scales.

A person who wants to safely remove psoriasis scales may need to try different methods to see what works best for them without damaging the skin or causing further irritation. While over-the-counter medications and home remedies can help reduce psoriasis scales, in severe cases people should see a doctor who can prescribe stronger treatments. People should also avoid personal triggers that could exacerbate any symptoms.

In this article, learn more about why psoriasis scales form, how to safely remove them, and what to avoid.

Psoriasis is an autoimmune condition that causes skin cells to multiply very quickly. This overgrowth can result in thick, scaly plaques that itch and cause discomfort.

There are many different types of psoriasis, with each type differing in appearance and the areas they affect. Research suggests that more than 8 million people in the United States have psoriasis and roughly 8090% have plaque psoriasis, which is the type that presents with psoriasis scales.

Psoriasis patches form as a result of an overactive immune system response. The raised plaques on the skin are actually a buildup of skin cells.

Normally, it takes roughly a month for new skin cells to grow and old ones to flake off. In a person with psoriasis, this process happens much faster. The National Psoriasis Foundation notes that the skin cells of a person with psoriasis may shed in just 3-4 days, which is many times faster than usual.

The skin cannot shed away these extra cells fast enough, and they build up on top of each other. The buildup of these skin cells results in the characteristic plaques of psoriasis. As the skin cells build up, the old skin cells stay on top of the skin and begin to shed away in larger flakes, called scales.

Removing the silvery scales from plaques may improve the look and feel of the plaques and may reduce some symptoms or make them more tolerable. Removing dead skin may also make medications more effective, as they can absorb into active skin cells rather than old or dead skin cells. Some options may include:

Some chemical exfoliators may be very helpful for psoriasis scales. OTC chemical exfoliators may be helpful in removing scale in mild to moderate cases. Doctors may prescribe stronger versions of these topical medications in some cases.

Common chemical exfoliators such as salicylic acid are widely available and may be effective for many people.

Salicylic acid is a keratolytic, meaning it helps break away the outermost layers of skin. A 2017 article notes that salicylic acid can help reduce the pH of the skin, which in turn increases the amount of moisture in the skin and softens the cells.

However, salicylic acid may cause side effects such as stinging, burning, or irritation. Other exfoliators may be similar to salicylic acid, but gentler on the skin. This includes alpha-hydroxy acids (AHAs) such as glycolic acid or lactic acid.

Regular moisturizers are important for healthy skin. This may be more apparent in people with psoriasis. Applying moisturizers regularly may help reduce the visibility of scales on psoriasis patches. It may also help reduce some symptoms, such as itching caused by very dry skin.

Dermatologists may recommend using heavier creams to help lock in moisture and provide an additional barrier to the skin.

Coal tar is an anti-inflammatory that may help reduce redness and itching. A 2017 article notes that most chronic plaques treated with coal tar improve after 1 month of treatment and remain in remission longer than with other topical treatments.

Some OTC coal tar products such as soaps or creams contain less coal tar than prescription-strength treatments, and may be more suited for daily upkeep. However, coal tar products may cause side effects such as:

A dermatologist may suggest using topical corticosteroids at varying strengths for treating all grades of psoriasis. OTC steroid creams are milder versions of prescription steroids and may help control mild symptoms of psoriasis.

Corticosteroids reduce inflammation in the plaques, slow down the growth of skin cells, and slightly suppress the immune system response behind these issues.

However, corticosteroids may cause side effects such as:

Soaking in the bath may help soften and slough away dead skin cells from psoriasis plaques.

The temperature of the bath should be lukewarm to warm. Avoid using hot water, as this may irritate the skin even more. Adding ingredients such as oils, Epsom salt, Dead Sea salts, or oatmeal to a bath may help remove psoriasis scales and soothe itching.

People should try to avoid harsh soaps or fragrances, which may irritate the skin. Soaking in a tub for about 15 minutes before using other methods may help soften and prepare the skin.

Medicated shampoos containing salicylic acid, coal tar, or other acids may help control plaques on the scalp and surrounding skin. While other topical formulas may also work, these shampoos contain a special formulation to get the medicine through the hair and into the scalp.

In addition to the approaches above, a person may want to do the following:

While caring for mild psoriasis with OTC ingredients can help remove scales, it is also important to care for psoriasis in other ways, such as by avoiding personal triggers. Psoriasis triggers may make symptoms worse and make efforts to control or remove scales harder.

While each persons triggers may vary, the National Psoriasis Foundation lists some common triggers to try to avoid, such as:

Avoid picking at scales as a way to remove them. It is easy to pull too much of a scale off, leading to broken skin underneath. This could cause further irritation or bleeding that makes symptoms worse. Picking may also put the skin at an increased risk for infection.

If picking is a nervous habit, try finding something else to keep the hands occupied, such as holding a trinket or clicking a pen.

OTC ingredients and medications to remove psoriasis scales may help with cases of mild psoriasis. If these home remedies do not help control symptoms, a person should consult with a doctor.

Doctors can prescribe stronger medications that may be more effective in controlling plaques or eliminating scales in cases of moderate or severe psoriasis

Psoriasis may cause scales to form on the skin that can be uncomfortable and itchy. This is because psoriasis causes skin cells to multiply quickly. People can use various methods at home such as chemical exfoliators, moisturizers, and baths to help remove psoriasis scales and reduce symptoms.

It is also important to take other steps to help control psoriasis symptoms, such as avoiding personal triggers. Anyone having difficulty controlling their psoriasis symptoms or removing scales safely should see their doctor.

Read the original:
How to safely remove psoriasis patches on the skin - Medical News Today